NanoString will develop a companion diagnostic for Merck's anti-PD-1 immunotherapy based on immune-related gene expression signatures.
The firm is aiming at in vitro diagnostics, applied markets, and next-generation sequencing sample preparation.
The companies' first offering is expected to be a multiplex respiratory disease panel.
More than 10 percent of individuals in an unselected population carried recurrent syndrome-associated CNVs or rare autosomal CNVs with potential ties to cognitive ability.
The company has also received approvals for various molecular diagnostics in the US and Canada in recent months.
In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.
The new Riken president outlines some of his plans for the institute.
The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.
An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.